Grant Number Disease area RFA PI Name Institution Approved funds Project goal TR2-01829 Arthritis Early Translational II Peter Schultz Scripps Research Institute Cartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis $6,180,114 2- Development candidate DR1-01452 Blood Disorders Disease Team Research I Donald Kohn University of California, Los Angeles Stem Cell Gene Therapy for Sickle Cell Disease $8,834,129 3- FDA filing TR1-01249 Bone or Cartilage Disease Early Translational I Michael Longaker Stanford University Enhancing healing via Wnt-protein mediated activation of endogenous stem cells $5,964,258 2- Development candidate TR2-01821 Bone or Cartilage Disease Early Translational II Bruno Peault University of California, Los Angeles Harnessing native fat-residing stem cells for bone regeneration $5,359,076 2- Development candidate TR2-01780 Bone or Cartilage Disease Early Translational II Dan Gazit Cedars-Sinai Medical Center Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures $1,927,698 1- Proof of concept TR2-01816 Blood cancer Early Translational II Markus Muschen University of California, San Francisco Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $3,607,305 2- Development candidate DR1-01430 Blood cancer Disease Team Research I Dennis Carson University of California, San Diego Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) $19,999,826 3- FDA filing TR2-01789 Blood cancer Early Translational II Catriona Jamieson University of California, San Diego Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy $3,103,041 2- Development candidate DR1-01485 Blood cancer Disease Team Research I Irving Weissman Stanford University Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells $18,759,276 3- FDA filing TR2-01791 Brain cancer Early Translational II Noriyuki Kasahara University of California, Los Angeles Stem cell-based carriers for RCR vector delivery to glioblastoma $3,370,607 2- Development candidate DR1-01421 Brain cancer Disease Team Research I Karen Aboody Beckman Research Institute of City of Hope Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials $18,015,429 3- FDA filing DR1-01477 Solid Tumor Disease Team Research I Dennis Slamon University of California, Los Angeles THERAPEUTIC OPPORTUNITIES TO TARGET TUMOR INITIATING CELLS IN SOLID TUMORS $19,979,660 3- FDA filing DR1-01423 Diabetes Disease Team Research I Allan Robins ViaCyte, Inc. Cell Therapy for Diabetes $22,999,933 3- FDA filing DR1-01490 HIV/AIDS Disease Team Research I John Zaia Beckman Research Institute of City of Hope ZIinc Finger Nuclease-Based Stem Cell Therapy for AIDS $14,573,835 3- FDA filing DR1-06893 HIV/AIDS Disease Team Research I Geoff Symonds Calimmune, Inc. GENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE $8,278,722 4- Early phase clinical trials TR2-01771 HIV/AIDS Early Translational II David DiGiusto Beckman Research Institute of City of Hope Development of RNA-based approaches to stem cell gene therapy for HIV $3,124,130 2- Development candidate TR2-01857 Liver Disease Early Translational II Mark Zern University of California, Davis Liver Cell Transplantation $4,216,113 2- Development candidate TR2-01756 Muscular Dystrophy Early Translational II Michele Calos Stanford University Stem Cell Therapy for Duchenne Muscular Dystrophy $2,267,900 1- Proof of concept TR2-01814 Autism Early Translational II Alysson Muotri University of California, San Diego Developing a drug-screening system for Autism Spectrum Disorders using human neurons $1,407,535 1- Proof of concept TR2-01841 Huntington's Disease Early Translational II Leslie Thompson University of California, Irvine A hESc-based Development Candidate for Huntington's Disease $3,539,536 2- Development candidate TR1-01267 Parkinson's disease Early Translational I Evan Snyder Sanford-Burnham Medical Research Institute Developmental Candidates for Cell-Based Therapies for Parkinson's Disease (PD) $5,190,752 2- Development candidate TR2-01778 Parkinson's disease Early Translational II Fred Gage The Salk Institute for Biological Studies Crosstalk: Inflammation in Parkinson’s disease (PD) in a humanized in vitro model $2,472,839 1- Proof of concept TR2-01856 Parkinson's disease Early Translational II Xianmin Zeng Buck Institute for Age Research Banking transplant ready dopaminergic neurons using a scalable process $4,998,871 2- Development candidate TR2-01785 Spinal Cord Injury Early Translational II leif Havton University of California, Irvine Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons $1,614,231 1- Proof of concept DR1-01480 Stroke Disease Team Research I Gary Steinberg Stanford University Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke $20,000,000 3- FDA filing TR2-01787 Skin Disease Early Translational II Roslyn Isseroff University of California, Davis Bone Marrow Mesenchymal Stem Cells to Heal Chronic Diabetic Wounds $4,635,576 2- Development candidate DR1-01454 Skin Disease Disease Team Research I Alfred Lane Stanford University iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa $11,039,208 3- FDA filing TR2-01767 Trauma Early Translational II Brian Cummings University of California, Irvine Neural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury $1,517,767 1- Proof of concept DR1-01444 Vision Loss Disease Team Research I Mark Humayun University of Southern California Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $18,904,916 3- FDA filing TR2-01768 Vision Loss Early Translational II Sophie Deng University of California, Los Angeles Regeneration of Functional Human Corneal Epithelial Progenitor Cells $1,524,947 1- Proof of concept TR2-01749 Epilepsy Early Translational II Arturo Alvarez-Buylla University of California, San Francisco Inhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy $1,564,016 1- Proof of concept TR2-01832 Canavan disease Early Translational II Yanhong Shi Beckman Research Institute of City of Hope Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell $1,835,983 1- Proof of concept